Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Accumulated Expenses (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Accumulated Expenses for 17 consecutive years, with $130.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 7.04% to $130.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $130.5 million through Dec 2025, up 7.04% year-over-year, with the annual reading at $130.5 million for FY2025, 7.04% up from the prior year.
  • Accumulated Expenses hit $130.5 million in Q4 2025 for Integra Lifesciences Holdings, down from $132.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $137.4 million in Q1 2025 to a low of $64.6 million in Q2 2023.
  • Historically, Accumulated Expenses has averaged $98.0 million across 5 years, with a median of $96.3 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: soared 60.97% in 2022 and later plummeted 34.69% in 2025.
  • Year by year, Accumulated Expenses stood at $92.7 million in 2021, then fell by 14.99% to $78.8 million in 2022, then grew by 28.02% to $100.8 million in 2023, then rose by 20.89% to $121.9 million in 2024, then grew by 7.04% to $130.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for IART at $130.5 million in Q4 2025, $132.9 million in Q3 2025, and $66.9 million in Q2 2025.